News

Please click here to see the latest news stories relating to Covid-19
 
 

Bionow members are welcome to submit PR items to this newsroom for all to see. Describing current activity and progress in the sector, it's a great place to promote your orgnaisation and keep up to date with the latest developments.

Whether currently a member or not, also keep up to date with all the latest news and events by registering to receive the Bionow newsletter.

Sygnature has significantly expanded our DMPK capabilities and expertise with the acquisition of XenoGesis, the UK’s largest independent laboratory-based CRO specialising in pre-clinical D...

Viva Biotech and SYNthesis Enters a Strategic Acquisition Agreement, Accelerating the Development of Global Innovative Drug R & D Service Capabilities

Peak Proteins is a contract research organisation providing protein production and structure determination services. We chat to CEO of Peak Proteins, Dr. Mark Abbott.

Today, Medicines Discovery Catapult (MDC) announce the rapid expansion of its Biosamples supply network, creating one of the largest virtual biobanks worldwide accessible to life science inn...

Sygnature Discovery, a leading independent integrated drug discovery and pre-clinical services company, is further strengthening its oncology and immuno-oncology capabilities with the acquis...

Medicines Discovery Catapult, Retrogenix and Peak Proteins announce a collaboration to advance understanding of the cellular mechanisms of infection by COVID-19.

Dr Tomas Adomavicius joins Peak Proteins as a Protein Purification Expert. Tomas graduated from Vilnius University in Lithuania before coming to the UK to continue his studies.

Last week the Government announced the establishment of large scale national COVID-19 hub laboratories across the UK. The initial laboratories have been established in Cheshire, Milton Keyne...

Medicines Discovery Catapult (MDC) have welcomed a cohort of MRC-funded PhD students as part of a training, talent and skills agenda to help develop the next generation of drug discovery res...

Cresset Discovery Services has been contracted by PhoreMost Limited to work on a novel oncology protein target.

Limited number of computational chemistry consultancy sessions for start-ups and small to medium sized enterprises (SMEs) and academics working on drug discovery projects.

Biosignatures has raised £3.5m to fund its goal of developing 20 novel diagnostic screening tests.

Our Valued Sponsors & Partners